CDXC Quote, Financials, Valuation and Earnings

Better Choice has a net margin of 7.34% compared to ChromaDex's net margin of 13.42%. ChromaDex's return on equity of 4.96% beat Better Choice's return on equity of -199.75%.

ChromaDex has a consensus price target of $6.08, signalling upside risk potential of 46.06%. On the other hand Better Choice has an analysts' consensus of -- which suggests that it could grow by 356.62%. Given that Better Choice has higher upside potential than ChromaDex, analysts believe Better Choice is more attractive than ChromaDex.

ChromaDex has a beta of 2.209, which suggesting that the stock is 120.901% more volatile than S&P 500. In comparison Better Choice has a beta of 0.669, suggesting its less volatile than the S&P 500 by 33.134%.

ChromaDex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Better Choice offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ChromaDex pays -- of its earnings as a dividend. Better Choice pays out -- of its earnings as a dividend.

ChromaDex quarterly revenues are $25.6M, which are larger than Better Choice quarterly revenues of $11.4M. ChromaDex's net income of $1.9M is higher than Better Choice's net income of $1.5M. Notably, ChromaDex's price-to-earnings ratio is 556.07x while Better Choice's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ChromaDex is 4.51x versus 0.07x for Better Choice. Usually stocks with elevated PS ratios are considered overvalued.

The Kraft Heinz has a net margin of 7.34% compared to ChromaDex's net margin of -4.54%. ChromaDex's return on equity of 4.96% beat The Kraft Heinz's return on equity of 2.78%.

ChromaDex has a consensus price target of $6.08, signalling upside risk potential of 46.06%. On the other hand The Kraft Heinz has an analysts' consensus of $37.30 which suggests that it could grow by 25.74%. Given that ChromaDex has higher upside potential than The Kraft Heinz, analysts believe ChromaDex is more attractive than The Kraft Heinz.

ChromaDex has a beta of 2.209, which suggesting that the stock is 120.901% more volatile than S&P 500. In comparison The Kraft Heinz has a beta of 0.481, suggesting its less volatile than the S&P 500 by 51.892%.

ChromaDex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Kraft Heinz offers a yield of 5.4% to investors and pays a quarterly dividend of $0.40 per share. ChromaDex pays -- of its earnings as a dividend. The Kraft Heinz pays out 68.83% of its earnings as a dividend. The Kraft Heinz's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ChromaDex quarterly revenues are $25.6M, which are smaller than The Kraft Heinz quarterly revenues of $6.4B. ChromaDex's net income of $1.9M is higher than The Kraft Heinz's net income of -$290M. Notably, ChromaDex's price-to-earnings ratio is 556.07x while The Kraft Heinz's PE ratio is 26.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ChromaDex is 4.51x versus 1.39x for The Kraft Heinz. Usually stocks with elevated PS ratios are considered overvalued.

Lifevantage has a net margin of 7.34% compared to ChromaDex's net margin of 3.87%. ChromaDex's return on equity of 4.96% beat Lifevantage's return on equity of 15.08%.

ChromaDex has a consensus price target of $6.08, signalling upside risk potential of 46.06%. On the other hand Lifevantage has an analysts' consensus of -- which suggests that it could grow by 30.2%. Given that ChromaDex has higher upside potential than Lifevantage, analysts believe ChromaDex is more attractive than Lifevantage.

ChromaDex has a beta of 2.209, which suggesting that the stock is 120.901% more volatile than S&P 500. In comparison Lifevantage has a beta of 0.821, suggesting its less volatile than the S&P 500 by 17.93%.

ChromaDex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifevantage offers a yield of 0.78% to investors and pays a quarterly dividend of $0.04 per share. ChromaDex pays -- of its earnings as a dividend. Lifevantage pays out 236.3% of its earnings as a dividend.

ChromaDex quarterly revenues are $25.6M, which are smaller than Lifevantage quarterly revenues of $47.2M. ChromaDex's net income of $1.9M is higher than Lifevantage's net income of $1.8M. Notably, ChromaDex's price-to-earnings ratio is 556.07x while Lifevantage's PE ratio is 62.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ChromaDex is 4.51x versus 1.31x for Lifevantage. Usually stocks with elevated PS ratios are considered overvalued.

Laird Superfood has a net margin of 7.34% compared to ChromaDex's net margin of -1.41%. ChromaDex's return on equity of 4.96% beat Laird Superfood's return on equity of -9.88%.

ChromaDex has a consensus price target of $6.08, signalling upside risk potential of 46.06%. On the other hand Laird Superfood has an analysts' consensus of $13.00 which suggests that it could grow by 82.07%. Given that Laird Superfood has higher upside potential than ChromaDex, analysts believe Laird Superfood is more attractive than ChromaDex.

ChromaDex has a beta of 2.209, which suggesting that the stock is 120.901% more volatile than S&P 500. In comparison Laird Superfood has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

ChromaDex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Laird Superfood offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ChromaDex pays -- of its earnings as a dividend. Laird Superfood pays out -- of its earnings as a dividend.

ChromaDex quarterly revenues are $25.6M, which are larger than Laird Superfood quarterly revenues of $11.8M. ChromaDex's net income of $1.9M is higher than Laird Superfood's net income of -$166.1K. Notably, ChromaDex's price-to-earnings ratio is 556.07x while Laird Superfood's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ChromaDex is 4.51x versus 1.70x for Laird Superfood. Usually stocks with elevated PS ratios are considered overvalued.